Forecast Ledgerinterventional psychiatry and psychedelic medicineQuoted, dated predictions scored against public outcomes under one written method. Every score links to the words, the rule and the evidence.

Trial outcomes

Rules 1.1.0 · as of 14 Sep 2026

Topline results, effect sizes, publications and terminations of named clinical programs in interventional psychiatry and psychedelic medicine.

Leaderboard

No forecaster has 5 resolved events yet.

score95% rangeprovisional (under 30 events)resolved events toward the 5 a score needsreference rowcoin flip 0.25
COIN FLIPANGERMAYER3of 5DOBLIN3of 5MUIR3of 500.10.20.30.40.5← BETTERBRIER
How to read
Persons are ranked only when both have 5 or more resolvedA cluster with at least one scored item. Only resolved clusters count toward n. Method › events, share a coverage tierHow completely a person's claims were collected: A complete archive, B archive plus search, C search-built. Ranks are shown only inside one tier. Method ›, and their intervalsThe 2.5 and 97.5 percentiles of a statistic over many resamples of the clusters with replacement, drawn with a seeded generator so every run gives the same interval. It shows how much the number could move if the events were redrawn. Method › do not overlap; otherwise rows are alphabetical. The evidence tierHow much resolved evidence a person has: T0 fewer than 10 clusters (counts only), T1 10 to 29 (provisional), T2 30 or more (full). Method › sets whether a row shows a score or a count. Comparators are ad hoc collections (tier C): they get a score at the same minimum, but a search-built corpus under-counts claims, so they are never ranked against the full archive. The reference rowsA leaderboard row that is not a person: the base rate or the market, scored with its own probability on the same clusters. Shows what a rule of thumb would have scored. Method › are scored on the same events; the coin flipThe constant 0.25, the Brier score of saying 0.50 on every item. Drawn as a reference line; not a row on the leaderboard. Method › is the score of saying fifty-fifty every time.

Trial outcomes · 9 events

Status

3 of 10 resolved claims came true.

TRUETRUE3FALSEFALSE7KNOWN TRUEKNOWN TRUE6PENDINGPENDING218ITEMS1 TICK = 1 ITEM

Trial outcomes · 18 items

Claims and events

18 claims against 44 events in the field.

saiddueevent
10 May 2021 · MAPS PBC (MAPP1): Nature Medicine publishes MAPP1 phase 3: MDMA-assisted therapy beat placebo-withMAPS PBC (MAPP1): NATURE MEDICINE PUBLISHES MAPP1 PHASE 3: MDMA-ASSISTED THERAPY BEAT PLACEBO-WITH29 Oct 2021 · Stanford (SNT/SAINT): American Journal of Psychiatry publishes double-blind sham-controlled RCT of Sta8 Aug 2022 · Karuna Therapeutics (KarXT, EMERGENT-2): Karuna reports positive phase 3 EMERGENT-2: KarXT beat placebo on PANSS total sc3 Nov 2022 · Compass Pathways (COMP360 phase 2b): NEJM publishes Compass phase 2b: a single 25 mg COMP360 psilocybin dose beat 1 m8 Dec 2022 · Relmada Therapeutics (REL-1017): Relmada's esmethadone fails a second large phase 3 depression trial two months a20 Mar 2023 · Karuna Therapeutics (KarXT, EMERGENT-3): Karuna reports positive phase 3 EMERGENT-3, its third positive registrational Ka24 May 2023 · ELEKT-D (ketamine vs ECT): NEJM publishes ELEKT-D: subanesthetic IV ketamine was noninferior to ECT in 403 21 Jul 2023 · Neurolief (Relivion DP, MOOD trial): Neurolief reports a positive interim analysis of its MOOD pivotal trial of at-ho31 Aug 2023 · Usona Institute (PSIL201): JAMA publishes Usona's phase 2 PSIL201: a single 25 mg psilocybin dose beat niac14 Sep 2023 · MAPS PBC (MAPP2): Nature Medicine publishes confirmatory phase 3 MAPP2 of MDMA-assisted therapy in5 Oct 2023 · Johnson & Johnson (Spravato, ESCAPE-TRD): NEJM publishes ESCAPE-TRD: esketamine nasal spray beat quetiapine XR on remissio30 Nov 2023 · Cybin (CYB003): Cybin reports positive phase 2 topline for deuterated psilocybin analog CYB003 i14 Dec 2023 · MindMed (MM120, phase 2b GAD): MindMed reports positive phase 2b of MM120 (LSD) in GAD with dose-dependent HAM-5 Jan 2024 · Stanford Medicine / VETS (magnesium-ibogaine): Nature Medicine publishes Stanford's open-label magnesium-ibogaine study in 30 s20 Mar 2024 · Usona Institute (uAspire / PSIL301): Usona launches phase 3 uAspire: single 25 mg psilocybin dose vs placebo in about30 May 2024 · Johnson & Johnson (seltorexant, MDD3001): J&J reports phase 3 MDD3001: adjunctive seltorexant met all primary and secondar11 Aug 2024 · MAPS / Lykos (Psychopharmacology): Psychopharmacology retracts three MDMA-assisted therapy papers by MAPS/Lykos aut22 Oct 2024 · Alto Neuroscience (ALTO-100): Alto's biomarker-selected phase 2b of ALTO-100 in MDD misses its primary MADRS e11 Nov 2024 · AbbVie (emraclidine, EMPOWER-1/2): AbbVie's muscarinic agonist emraclidine, acquired via the $8.7B Cerevel deal, fa18 Nov 2024 · Cybin (CYB003): Cybin reports 12-month phase 2 follow-up for CYB003 in MDD with sustained respon3 Dec 2024 · US Department of Veterans Affairs: VA announces funding for its first study of MDMA-assisted therapy in decades, fo9 Dec 2024 · Relmada Therapeutics (REL-1017): Relmada halts its two remaining phase 3 trials of esmethadone after a futility s2 Jan 2025 · Neumora Therapeutics (navacaprant, KOASTAL-1): Neumora's phase 3 KOASTAL-1 of kappa-opioid antagonist navacaprant in MDD misses3 Feb 2025 · GH Research (GH001): GH Research reports its phase 2b of inhaled mebufotenin (5-MeO-DMT) GH001 in TRD12 Feb 2025 · Alto Neuroscience (ALTO-300): Alto reports a favorable interim analysis of its EEG-biomarker phase 2b of adjun3 Mar 2025 · Neumora Therapeutics (navacaprant): Neumora halts one navacaprant depression trial and redesigns the KOASTAL-2 and K6 Mar 2025 · Johnson & Johnson (aticaprant, VENTURA): J&J stops the phase 3 VENTURA program of kappa-opioid antagonist aticaprant in M22 Apr 2025 · Bristol Myers Squibb (Cobenfy, ARISE): Phase 3 ARISE misses: adjunctive Cobenfy did not significantly beat placebo on P23 Jun 2025 · Compass Pathways (COMP360, COMP005): Compass reports phase 3 COMP005 met its primary endpoint: a single 25 mg COMP3601 Jul 2025 · atai Life Sciences / Beckley Psytech (BPL-003): Phase 2b of single-dose intranasal BPL-003 (5-MeO-DMT) in TRD meets primary and 4 Sep 2025 · MindMed (MM120): JAMA publishes MindMed's phase 2b of MM120 in GAD, the first placebo-controlled 22 Sep 2025 · Johnson & Johnson (seltorexant, MDD3005): Phase 3 MDD3005 misses its primary endpoint: seltorexant showed only numerically3 Dec 2025 · Bristol Myers Squibb (Cobenfy, ADEPT-2): BMS delays the ADEPT-2 phase 3 readout in Alzheimer's disease psychosis to end-217 Feb 2026 · Compass Pathways (COMP360, COMP006): Second phase 3 COMP006 meets primary endpoint: two 25 mg COMP360 doses 3 weeks a5 Mar 2026 · Helus Pharma (HLP004 / CYB004, GAD): Helus reports phase 2 signal-detection results for deuterated DMT HLP004 in mode1 Apr 2026 · Alto Neuroscience (ALTO-101): Alto's phase 2 proof-of-concept of ALTO-101 in cognitive impairment associated w8 Apr 2026 · AtaiBeckley (BPL-003): AtaiBeckley publishes phase 2a data of BPL-003 in TRD patients on SSRIs (CNS Dru26 May 2026 · US Department of Veterans Affairs: VA launches its MDMA-assisted therapy trial for veterans with PTSD and alcohol u15 Jun 2026 · Neumora Therapeutics (navacaprant, KOASTAL-2/3): KOASTAL-2 and KOASTAL-3 both miss; Neumora discontinues navacaprant after three 22 Jun 2026 · Definium Therapeutics (DT120 / MM120, Emerge): Phase 3 Emerge of single-dose DT120 (LSD) ODT 100 µg in MDD meets its primary en7 Jul 2026 · Compass Pathways (COMP360, COMP006): COMP006 26-week (Part B) data show benefit of two 25 mg doses maintained on aver21 Jul 2026 · Helus Pharma (HLP003 / CYB003, APPROACH): Helus completes enrollment in the phase 3 APPROACH study of HLP003 as adjunctive12 Aug 2026 · Definium Therapeutics (DT120 / MM120, Voyage): Phase 3 Voyage of DT120 ODT 100 µg in GAD meets its primary HAM-A endpoint at we9 Sep 2026 · Compass Pathways (COMP360, COMP005 Part C): Compass reports 52-week open-label COMP005 data: participants who received an adMAPP1 PHASE 3 TRI…MAPP1 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · stated 14 Jan 2019MAPP1 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · restated 14 Jan 2019 · p 70%MAPP1 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · miss 14 Jan 2021A SECOND SPONSOR…A second sponsor pursues its own MDMA-for-PTSD program with its own clinical data · stated 10 Sep 2019A second sponsor pursues its own MDMA-for-PTSD program with its own clinical data · restated 10 Sep 2019 · p 30%A second sponsor pursues its own MDMA-for-PTSD program with its own clinical data · miss 10 Sep 2021MAPP1 PHASE 3 TRI…MAPP1 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · stated 26 Aug 2020MAPP1 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · restated 26 Aug 2020 · p 90%MAPP1 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · hit 3 May 2021SNT OR ACCELERATE…SNT or accelerated iTBS for depression: a subsequent RCT meets its primary endpoint · stated 11 Jul 2022SNT or accelerated iTBS for depression: a subsequent RCT meets its primary endpoint · restated 11 Jul 2022 · p 90%SNT or accelerated iTBS for depression: a subsequent RCT meets its primary endpoint · hit 10 Jul 2024MAPP2 PHASE 3 TRI…MAPP2 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · stated 12 Dec 2022MAPP2 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · restated 12 Dec 2022 · p 70%MAPP2 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · miss 31 Dec 2022PCN-101 (ARKETAMI…PCN-101 (arketamine) development is discontinued · stated 29 Mar 2024PCN-101 (arketamine) development is discontinued · restated 29 Mar 2024 · p 30%PCN-101 (arketamine) development is discontinued · miss 29 Mar 2026COMPASS PATHWAYS…Compass Pathways reports its first COMP360 Phase 3 topline readout · stated 8 May 2024Compass Pathways reports its first COMP360 Phase 3 topline readout · restated 8 May 2024 · p 90%Compass Pathways reports its first COMP360 Phase 3 topline readout · miss 31 Dec 2024A COMP360 (PSILOC…A COMP360 (psilocybin) Phase 3 trial in treatment-resistant depression meets its primary endpoint · stated 8 May 2024A COMP360 (psilocybin) Phase 3 trial in treatment-resistant depression meets its primary endpoint · restated 8 May 2024 · p 80%A COMP360 (psilocybin) Phase 3 trial in treatment-resistant depression meets its primary endpoint · hit 23 Jun 2025A COMP360 (PSILOC…A COMP360 (psilocybin) Phase 3 trial in treatment-resistant depression meets its primary endpoint · stated 30 Sep 2024A COMP360 (psilocybin) Phase 3 trial in treatment-resistant depression meets its primary endpoint · restated 30 Sep 2024 · p 70%EARLY-TMS TRIAL (…Early-TMS trial (rTMS/iTBS versus SSRI for depression in pregnancy) reports its primary result · stated 30 Mar 2025Early-TMS trial (rTMS/iTBS versus SSRI for depression in pregnancy) reports its primary result · restated 30 Mar 2025 · p 90%Early-TMS trial (rTMS/iTBS versus SSRI for depression in pregnancy) reports its primary result · miss 31 Dec 2025BPL-003 TWO-DOSE…BPL-003 two-dose induction reports a larger antidepressant effect than the single-dose Phase 2b result · stated 1 Jul 2025BPL-003 two-dose induction reports a larger antidepressant effect than the single-dose Phase 2b result · restated 1 Jul 2025 · p 50%VLS-01 (DMT) PHAS…VLS-01 (DMT) Phase 2 trial in treatment-resistant depression meets its primary endpoint · stated 28 Jul 2025VLS-01 (DMT) Phase 2 trial in treatment-resistant depression meets its primary endpoint · restated 28 Jul 2025 · p 90%VLS-01 (DMT) Phase 2 trial in treatment-resistant depression meets its primary endpoint · miss 31 Mar 2026SANMAI TRANSCRANI…Sanmai transcranial focused ultrasound trial reports topline results · stated 1 Jan 2026Sanmai transcranial focused ultrasound trial reports topline results · restated 1 Jan 2026 · p 70%MONARCH ETNS LARG…Monarch eTNS large-scale replication trial results are published · stated 15 Jan 2026Monarch eTNS large-scale replication trial results are published · restated 15 Jan 2026 · p 70%BPL-003 TWO-DOSE…BPL-003 two-dose induction reports a larger antidepressant effect than the single-dose Phase 2b result · stated 18 Feb 2026BPL-003 two-dose induction reports a larger antidepressant effect than the single-dose Phase 2b result · restated 18 Feb 2026 · p 50%KALE AWARD TRIAL…Kale Award trial (bilateral versus unilateral TMS for suicidal ideation) reports its primary result · stated 25 Feb 2026Kale Award trial (bilateral versus unilateral TMS for suicidal ideation) reports its primary result · restated 25 Feb 2026 · p 10%THE NEXT DT120 (M…The next DT120 (MM120, LSD) Phase 3 topline meets its primary endpoint · stated 7 May 2026The next DT120 (MM120, LSD) Phase 3 topline meets its primary endpoint · restated 7 May 2026 · p 90%DT120 (LSD) VOYAG…DT120 (LSD) Voyage Phase 3 trial in generalized anxiety disorder reports its topline result · stated 2 Jul 2026DT120 (LSD) Voyage Phase 3 trial in generalized anxiety disorder reports its topline result · restated 2 Jul 2026 · p 70%TODAY20202022202420262028

Headline panel · Trial outcomes

Claims

18 claims since 2019; 10 resolved, 8 pending.

truefalsependingvoid
201920202021202220232024202520262027202814 JAN 2019MAPP1 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · false · p 70%AFF10 SEP 2019A second sponsor pursues its own MDMA-for-PTSD program with its own clinical data · false · p 30%AFF26 AUG 2020MAPP1 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · true · p 90%AFF11 JUL 2022SNT or accelerated iTBS for depression: a subsequent RCT meets its primary endpoint · true · p 90%12 DEC 2022MAPP2 Phase 3 trial of MDMA-assisted therapy for PTSD meets its primary endpoint · false · p 70%AFF29 MAR 2024PCN-101 (arketamine) development is discontinued · false · p 30%8 MAY 2024A COMP360 (psilocybin) Phase 3 trial in treatment-resistant depression meets its primary endpoint · true · p 80%AFF8 MAY 2024Compass Pathways reports its first COMP360 Phase 3 topline readout · false · p 90%AFF30 SEP 2024A COMP360 (psilocybin) Phase 3 trial in treatment-resistant depression meets its primary endpoint · pending · p 70%AFF30 MAR 2025Early-TMS trial (rTMS/iTBS versus SSRI for depression in pregnancy) reports its primary result · false · p 90%1 JUL 2025BPL-003 two-dose induction reports a larger antidepressant effect than the single-dose Phase 2b result · pending · p 50%AFF28 JUL 2025VLS-01 (DMT) Phase 2 trial in treatment-resistant depression meets its primary endpoint · false · p 90%AFF1 JAN 2026Sanmai transcranial focused ultrasound trial reports topline results · pending · p 70%15 JAN 2026Monarch eTNS large-scale replication trial results are published · pending · p 70%18 FEB 2026BPL-003 two-dose induction reports a larger antidepressant effect than the single-dose Phase 2b result · pending · p 50%AFF25 FEB 2026Kale Award trial (bilateral versus unilateral TMS for suicidal ideation) reports its primary result · pending · p 10%7 MAY 2026The next DT120 (MM120, LSD) Phase 3 topline meets its primary endpoint · pending · p 90%2 JUL 2026DT120 (LSD) Voyage Phase 3 trial in generalized anxiety disorder reports its topline result · pending · p 70%TODAYDOT AREA = P · HAIRLINE = SAID TO DUE

Trial outcomes · all admitted items